| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
1 Department of Surgery, Melanoma and Sarcoma Unit, National Cancer Institute of Milan, Via Venezian, 1, 20133 Milan, Italy
2 Department of Surgery, Surgical Oncology Unit, Centre Hospitalier de l’Université de Montreal, University of Montreal Health Center, Montreal, Canada
3 Department of Obstetrics and Gynecology, School of Medical Science, Universidade Estadual de Campinas, Campinas, Brazil
4 Unit of Emergency Surgery and Organ Transplant, Università degli Studi di Messina, Policlinico G. Martino, Messina, Italy
5 Department of Anesthesiology, National Cancer Institute of Milan, Via Venezian, 1, 20133 Milan, Italy
6 Department of Critical Care, National Cancer Institute of Milan, Via Venezian, 1, 20133 Milan, Italy
7 Nutritional Care Unit, National Cancer Institute of Milan, Via Venezian, 1, 20133 Milan, Italy
Correspondence: Address correspondence and reprint requests to: Marcello Deraco, MD; E-mail: marcello.deraco{at}istitutotumori.mi.it
Background: Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP) are increasingly used in the management of carcinomatosis of various sites of origin. We analyzed the risk factors for bowel complications with primary anastomoses and the closed technique for IPHP.
Methods: From 1995 to 2004, 203 consecutive procedures were performed at the National Cancer Institute of Milan. We retrospectively analyzed this series of patients. Treated pathologies included peritoneal mesothelioma; pseudomyxoma peritonei; colorectal, ovarian, or gastric carcinomatosis; and abdominal sarcomatosis. All digestive anastomoses were performed before the IPHP. Only one defunctioning stoma was used.
Results: We found a bowel complication rate of 10.8%. The bowel complications:anastomoses ratio was 11.3%. On univariate analysis we found a statistically significant association between bowel complications and the following variables: sex, previous systemic chemotherapy status, number of anastomoses ( fewer than two vs. two or more), duration of the procedure (<8.7 vs. 
8.7 hours), and extent of cytoreduction. After multivariate analysis, male sex (odds ratio [OR], 4.2), no previous systemic chemotherapy (OR, 3.5), and duration of the procedure 8.7 hours (OR, 6.3) were considered independent risk factors for bowel complications.
Conclusions: Bowel complications are not increased when primary unprotected anastomoses are performed during peritonectomy and IPHP when the closed technique is used. Male sex, duration of the procedure, and no previous systemic chemotherapy are independent unfavorable risk factors.
Key Words: Peritoneal carcinomatosis • Peritonectomy • Intraperitoneal hyperthermic perfusion • Intestinal complications
This article has been cited by other articles:
 |
|
 |
|
  M. VAIRA, T. CIOPPA, G. DE MARCO, C. BING, S. D'AMICO, M. D'ALESSANDRO, G. FIORENTINI, and M. DE SIMONE Management of Pseudomyxoma Peritonei by Cytoreduction+HIPEC (Hyperthermic Intraperitoneal Chemotherapy): Results Analysis of a Twelve-year Experience In Vivo, July 1, 2009; 23(4): 639 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. ASERO, M. CARUSO, N. VALLONE, A.G. LUCIANI, V. LOMBARDO, G. TERRANOVA, G. ETTORE, and G. GIANNONE Cytoreductive Surgery (CS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treatment of Peritoneal Surface Malignances: Report of a Phase II Clinical Study In Vivo, July 1, 2009; 23(4): 645 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Aarts, R. P. Bleichrodt, B. de Man, R. Lomme, O. C. Boerman, and T. Hendriks The Effects of Adjuvant Experimental Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy on Intestinal and Abdominal Healing after Cytoreductive Surgery for Peritoneal Carcinomatosis in the Rat Ann. Surg. Oncol., November 1, 2008; 15(11): 3299 - 3307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kusamura, D. Baratti, A. Antonucci, R. Younan, B. Laterza, G. D. Oliva, C. Gavazzi, and M. Deraco Incidence of Postoperative Pancreatic Fistula and Hyperamylasemia after Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy Ann. Surg. Oncol., December 1, 2007; 14(12): 3443 - 3452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kusamura, D. Baratti, R. Younan, B. Laterza, G. D. Oliva, P. Costanzo, M. Favaro, C. Gavazzi, F. Grosso, and M. Deraco Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity Ann. Surg. Oncol., September 1, 2007; 14(9): 2550 - 2558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Yan, M. Links, S. Fransi, T. Jacques, D. Black, V. Saunders, and D. L. Morris Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy A Journey to Becoming a Nationally Funded Peritonectomy Center Ann. Surg. Oncol., August 1, 2007; 14(8): 2270 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Yan, J. Sim, and D. L. Morris Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Ann. Surg. Oncol., June 1, 2007; 14(6): 1807 - 1817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Yan, G. Edwards, R. Alderman, C. E. Marquardt, and P. H. Sugarbaker Morbidity and Mortality Assessment of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma--A Prospective Study of 70 Consecutive Cases Ann. Surg. Oncol., February 1, 2007; 14(2): 515 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Tuttle, Y. Zhang, E. Greeno, and A. Knutsen Toxicity and Quality of Life after Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Ann. Surg. Oncol., December 1, 2006; 13(12): 1627 - 1632. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
